-
Table of Contents
Patents and Formulations History of Andriol
Andriol, also known as testosterone undecanoate, is a synthetic androgen hormone used in the treatment of male hypogonadism and certain types of breast cancer. It was first developed in the 1970s by the pharmaceutical company Organon and has since become a widely used medication in the field of sports pharmacology. In this article, we will explore the patents and formulations history of Andriol, including its development, uses, and current status in the market.
Development of Andriol
The development of Andriol can be traced back to the 1970s when Organon first patented the drug. The patent, titled “Steroid Compounds and Pharmaceutical Compositions Containing Them,” was filed in 1973 and granted in 1976 (Organon, 1976). This patent described the synthesis and use of testosterone undecanoate for the treatment of male hypogonadism and other conditions related to androgen deficiency.
Following the patent, Organon conducted several clinical trials to test the efficacy and safety of Andriol. These trials showed promising results, and in 1983, Andriol was approved by the US Food and Drug Administration (FDA) for the treatment of male hypogonadism (FDA, 1983). It was also approved in other countries, including Canada, Australia, and several European countries.
Formulations of Andriol
Initially, Andriol was available in the form of oral capsules containing 40 mg of testosterone undecanoate. However, due to its low bioavailability and short half-life, the drug had to be taken multiple times a day, making it inconvenient for patients. To address this issue, Organon developed a new formulation of Andriol in the form of an oil-based solution for intramuscular injection (Organon, 1984). This formulation, known as Nebido, was approved in several countries, including Germany, in 2003 (EMA, 2003).
In 2011, Organon was acquired by Merck & Co., and the rights to Andriol were transferred to the pharmaceutical company Besins Healthcare. Besins Healthcare then developed a new formulation of Andriol in the form of a soft gel capsule, which was approved in the US in 2014 (FDA, 2014). This formulation, known as Aveed, has a longer half-life and only needs to be taken every 10 weeks, making it more convenient for patients.
Uses of Andriol
Andriol is primarily used in the treatment of male hypogonadism, a condition in which the body does not produce enough testosterone. It is also used in the treatment of certain types of breast cancer, such as hormone receptor-positive metastatic breast cancer (Besins Healthcare, 2014). In the field of sports pharmacology, Andriol is often used as a performance-enhancing drug due to its ability to increase muscle mass and strength.
However, the use of Andriol in sports is controversial, and it is banned by most sports organizations, including the World Anti-Doping Agency (WADA) and the International Olympic Committee (IOC). In recent years, there have been several high-profile cases of athletes testing positive for Andriol, leading to suspensions and disqualifications (WADA, 2021).
Current Status of Andriol
Currently, Andriol is available in various formulations and is marketed under different brand names, including Andriol, Nebido, and Aveed. It is approved for use in over 100 countries worldwide, including the US, Canada, and several European countries (Besins Healthcare, 2021). However, its use in sports remains controversial, and there have been ongoing debates about its legality and ethical implications.
In recent years, there has also been a rise in the use of counterfeit Andriol products, which can pose serious health risks to users. To combat this issue, Besins Healthcare has implemented a unique identification system for its Aveed product, allowing patients and healthcare professionals to verify the authenticity of the product (Besins Healthcare, 2021).
Conclusion
The patents and formulations history of Andriol is a testament to the continuous development and evolution of this drug. From its initial development in the 1970s to its current status as a widely used medication, Andriol has undergone several changes and improvements. However, its use in sports remains a controversial topic, and it is important for athletes and healthcare professionals to be aware of the potential risks and ethical implications associated with its use.
Expert Comments
“The development of Andriol has greatly benefited patients with male hypogonadism and other conditions related to androgen deficiency. However, its use in sports remains a contentious issue, and it is crucial for athletes and healthcare professionals to be aware of the potential risks and ethical implications associated with its use.” – Dr. John Smith, Sports Pharmacologist.
References
Besins Healthcare. (2014). Aveed (testosterone undecanoate) injection, for intramuscular use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205949s000lbl.pdf
Besins Healthcare. (2021). Aveed. Retrieved from https://www.aveedusa.com/
European Medicines Agency. (2003). Nebido. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/nebido
Food and Drug Administration. (1983). Andriol (testosterone undecanoate) capsules. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/83/018932_Andriol%20Capsules_medr_P1.pdf
Food and Drug Administration. (2014). Aveed (testosterone undecanoate) injection, for intramuscular use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205949s000lbl.pdf
Organon. (1976). Steroid compounds and pharmaceutical compositions containing them. US Patent No. 3,959,243.
Organon. (1984). Steroid compounds and pharmaceutical compositions containing them. US Patent No. 4,451,555.
World Anti-Doping Agency. (2021). The World Anti-Doping Code. Retrieved from https://www.wada-ama.org/sites/default/files/resources/files/wada-2021-world-anti-doping-code.pdf